Mar 15, 2024, 18:07
Talazoparib in Combination With Enzalutamide for Prostate Cancer – FDA Oncology
FDA Oncology posted on X/Twitter:
“FDA Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer – Journal of Clinical Oncology. 1st author Brian Heiss, last author Daniel Suzman.“
View additional information.
Source: FDA Oncology/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 2, 2024, 12:32
Dec 2, 2024, 12:31
Dec 2, 2024, 10:01
Dec 2, 2024, 09:04